Prostaglandin E(2) is involved in colon
carcinogenesis through its binding to the
PGE(2) receptor subtypes EP(1), EP(2), EP(3) and EP(4). We have demonstrated that administration of
ONO-8711, an EP(1)-selective antagonist, suppresses development of AOM-induced ACF in C57BL/6 mice and F344 rats.
ONO-8711 also reduced the numbers of
intestinal polyps in Min mice. In the present study, we investigated the long-term effects of
ONO-8711 on
colon cancer development in rats treated with AOM. Male F344 rats were injected subcutaneously with AOM (15 mg/kg
body weight) once a week for the first 2 weeks to develop
colon cancer. Administration of 400 or 800 p.p.m.
ONO-8711 in their diets for 32 weeks reduced the incidence, multiplicity and volume of colon
carcinomas. The incidence of
colon adenocarcinomas in AOM-treated rats was 97, 83 and 76% (P < 0.05) in the 0, 400 and 800 p.p.m. of
ONO-8711 groups, respectively. The multiplicity of
adenocarcinomas was also decreased significantly, being 3.31 +/- 0.33, 2.34 +/- 0.27 (P < 0.05) and 2.06 +/- 0.34 (P < 0.01) with 0, 400 and 800 p.p.m. of
ONO-8711, respectively. Moreover, treatment with 800 p.p.m.
ONO-8711 reduced the mean volume of
adenocarcinomas to 49% (P < 0.05) of the value for the AOM treatment alone. Furthermore, the
BrdU labeling index was decreased significantly in
colon cancer cells by 800 p.p.m.
ONO-8711. These results confirm that EP(1) is involved in colon
carcinogenesis and that EP(1)-selective antagonists might be promising candidates for
colon cancer chemopreventive agents.